Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / SRPT

Stock rating

Sarepta Therapeutics,, Inc. (SRPT) Stock Rating & Analysis

As of November 5, 2026, MELANY rates Sarepta Therapeutics,, Inc. 57 out of 100 (Very Promising). Its highest factor scores are valuation and earnings track record at 88, and its lowest is catalyst setup at 36.

MELANY ratingRated 2026-11-05

SRPT · composite score

57/100
Very Promising
Nov 5
Rating date
Live price in the app →
Quality41
Momentum50
Risk-adjusted75
Source basis SEC filings and live market dataDated snapshot

Why SRPT scores 57/100

SRPT's 8 factor scores run from 36 to 88, and 4 of them sit above its composite of 57. Here is how SRPT breaks down.

Valuation88/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

Business quality41/100

Margins, returns on capital, and balance-sheet strength.

  • Gross margin 59%
Price momentum50/100

Direction and relative strength of the recent share-price trend.

Earnings track record88/100

History of beating or missing estimates, and where estimates are heading.

  • Avg EPS beat +21%
Analyst sentiment64/100

What Wall Street price targets and revisions are signalling.

  • Institutional net buying +3.1%
Catalyst setup36/100

Near-term events that could move the stock.

Risk-adjusted profile75/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How SRPT compares

As of November 19, 2026, Sarepta Therapeutics,, Inc. ranks 11th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 55.

All stock rating pages.

Key risks for SRPT

  • Operating margin -7%, cash-burn business, dependent on capital markets
  • Short interest 25% of float, high volatility risk on news
  • Performance partly driven by Healthcare sector, rotation away from this theme would hurt
  • No positive trailing earnings, valuation cannot be anchored to current P/E

Sector and theme context

Sarepta Therapeutics,, Inc. sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds SRPT's momentum and catalyst factors above.

SRPT trade plan (Pro)

MELANY has a full position plan for Sarepta Therapeutics,, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates SRPT

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Sarepta Therapeutics,, Inc.'s 57/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about SRPT

Is Sarepta Therapeutics,, Inc. (SRPT) a buy?

As of 2026-11-05, MELANY rated Sarepta Therapeutics,, Inc. Very Promising with a composite score of 57/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does SRPT rank against similar companies?

As of November 19, 2026, Sarepta Therapeutics,, Inc. ranks 11th of 20 in MELANY's GLP-1, Obesity and Biotech Stocks list, where the average score is 55. Among the other names in the list, the highest scores belong to REGN (74) and LLY (68).

Should I buy Sarepta Therapeutics,, Inc. stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Sarepta Therapeutics,, Inc. (SRPT) Very Promising with a composite of 57/100 as of 2026-11-05. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the SRPT stock price forecast?

MELANY does not publish price targets or forecasts for SRPT. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 57/100 across eight factors for Sarepta Therapeutics,, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for SRPT as of 2026-11-05: its analyst sentiment factor is 64/100 (Institutional net buying +3.1%), and its price momentum factor is 50/100.

Is SRPT stock overvalued or undervalued?

MELANY's valuation factor currently reads 88/100 for Sarepta Therapeutics,, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives SRPT's read.

What price should I buy SRPT at?

Rather than chasing the current price, MELANY computes a smart entry zone for SRPT: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying SRPT stock?

The top risks MELANY currently flags for Sarepta Therapeutics,, Inc.: Operating margin -7%, cash-burn business, dependent on capital markets; Short interest 25% of float, high volatility risk on news; Performance partly driven by Healthcare sector, rotation away from this theme would hurt; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Sarepta Therapeutics,, Inc. a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 41/100 for Sarepta Therapeutics,, Inc., and earnings track record, at 88/100. The 57/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will SRPT stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 50/100 for SRPT right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this SRPT rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-05, and the score is not recomputed on this page. MELANY re-scores SRPT as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, SRPT included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.